Christina Pfannenberg

List of Publications by Year
in descending order

50 papers	2,367 citations	257450 24 h-index	206112 48 g-index
52 all docs	52 docs citations	52 times ranked	3502 citing authors

#	Article	IF	Citations
1	Impact of Age on the Relationships of Brown Adipose Tissue With Sex and Adiposity in Humans. Diabetes, 2010, 59, 1789-1793.	0.6	349
2	Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 92-101.	6.4	237
3	Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. European Journal of Cancer, 2007, 43, 557-564.	2.8	188
4	18F-FDG-PET/CT to Select Patients with Peritoneal Carcinomatosis for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology, 2009, 16, 1295-1303.	1.5	141
5	Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial. Radiotherapy and Oncology, 2017, 124, 526-532.	0.6	107
6	Fast Whole-Body Assessment of Metastatic Disease Using a Novel Magnetic Resonance Imaging System. Investigative Radiology, 2005, 40, 64-71.	6.2	101
7	Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. European Journal of Cancer, 2006, 42, 342-350.	2.8	100
8	Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imaging. British Journal of Radiology, 2007, 80, 437-445.	2.2	96
9	Preoperative assessment of peritoneal carcinomatosis: intraindividual comparison of 18F-FDG PET/CT and MRI. Abdominal Imaging, 2013, 38, 64-71.	2.0	75
10	Correlation of Simultaneously Acquired Diffusion-Weighted Imaging and 2-Deoxy-[18F] fluoro-2-D-glucose Positron Emission Tomography of Pulmonary Lesions in a Dedicated Whole-Body Magnetic Resonance/Positron Emission Tomography System. Investigative Radiology, 2013, 48, 247-255.	6.2	68
11	Correlation of Brown Adipose Tissue with Other Body Fat Compartments and Patient Characteristics. Academic Radiology, 2018, 25, 102-110.	2.5	57
12	Multifunctional Profiling of Nonâ€“Small Cell Lung Cancer Using ¹⁸F-FDG PET/CT and Volume Perfusion CT. Journal of Nuclear Medicine, 2012, 53, 521-529.	5.0	49
13	Positron Emission Tomography/Computed Tomography and Whole-Body Magnetic Resonance Imaging in Staging of Advanced Nonsmall Cell Lung Cancer???Initial Results. Investigative Radiology, 2008, 43, 290-297.	6.2	47
14	18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 95-101.	6.4	46
15	Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo ¹⁸F-FDG-PET. Theranostics, 2020, 10, 925-937.	10.0	46
16	Is the standard uptake value (SUV) appropriate for quantification in clinical PET imaging? â€“ Variability induced by different SUV measurements and varying reconstruction methods. European Journal of Radiology, 2015, 84, 158-162.	2.6	42
17	The role of [18F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of postchemotherapy residual masses in metastatic germ cell tumors?prospects for management. World Journal of Urology, 2004, 22, 132-9.	2.2	40
18	Influence of 18F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 482-488.	6.4	37

#	Article	IF	Citations
19	Prospective Evaluation of a Tumor Control Probability Model Based on Dynamic ¹⁸F-FMISO PET for Head and Neck Cancer Radiotherapy. Journal of Nuclear Medicine, 2019, 60, 1698-1704.	5.0	37
20	PET/CT with 18F-FLT: Does It Improve the Therapeutic Management of Metastatic Germ Cell Tumors?. Journal of Nuclear Medicine, 2010, 51, 845-853.	5.0	36
21	Peritoneal carcinomatosis: comparison of dynamic contrast-enhanced magnetic resonance imaging with surgical and histopathologic findings. Abdominal Radiology, 2012, 37, 834-842.	2.1	31
22	Correlation between [18F]FDG PET/CT and volume perfusion CT in primary tumours and mediastinal lymph nodes of non-small-cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 677-684.	6.4	31
23	Practice-based evidence for the clinical benefit of PET/CTâ€"results of the first oncologic PET/CT registry in Germany. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 54-64.	6.4	30
24	Intention-to-Treat Analysis of ⁶⁸Ga-PSMA and ¹¹C-Choline PET/CT Versus CT for Prostate Cancer Recurrence After Surgery. Journal of Nuclear Medicine, 2019, 60, 1359-1365.	5.0	29
25	Fast non-enhanced abdominal examination protocols in PET/MRI for patients with neuroendocrine tumors (NET): comparison to multiphase contrast-enhanced PET/CT. Radiologia Medica, 2018, 123, 860-870.	7.7	26
26	Impact of 18F-FDG-PET/CT on surgical management in patients with advanced melanoma: an outcome based analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1312-1318.	6.4	23
27	Geometric analysis of loco-regional recurrences in relation to pre-treatment hypoxia in patients with head and neck cancer. Acta OncolÃ³gica, 2017, 56, 1571-1576.	1.8	23
28	Robustness of quantitative hypoxia PET image analysis for predicting local tumor control. Acta OncolÃ³gica, 2015, 54, 1364-1369.	1.8	22
29	Dose escalation to hypoxic subvolumes in head and neck cancer: A randomized phase II study using dynamic [18F]FMISO PET/CT. Radiotherapy and Oncology, 2022, 171, 30-36.	0.6	22
30	Is there a link between very early changes of primary and secondary lymphoid organs in ¹⁸F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy?. , 2020, 8, e000656.		21
31	Image-derived biomarkers and multimodal imaging strategies for lung cancer management. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 634-643.	6.4	20
32	Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer. Acta OncolÃ³gica, 2017, 56, 1577-1582.	1.8	20
33	Imaging giant cell arteritis and Aortitis in contrast enhanced 18F-FDG PET/CT: Which imaging score correlates best with laboratory inflammation markers?. European Journal of Radiology, 2018, 99, 94-102.	2.6	18
34	Dual-phase multidetector thin-section CT in detecting duodenal gastrinoma. Abdominal Imaging, 2005, 30, 543-547.	2.0	17
35	Impact of PET/CT on clinical management in patients with cancer of unknown primaryâ€"a PET/CT registry study. European Radiology, 2020, 30, 1325-1333.	4.5	17
36	EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa. Orphanet Journal of Rare Diseases, 2019, 14, 278.	2.7	16

#	Article	IF	Citations
37	MR cholangiography in the diagnosis of sclerosing cholangitis in Langerhans' cell histiocytosis. European Radiology, 2001, 11, 2516-2520.	4.5	14
38	Clinical and prognostic value of tumor volumetric parameters in melanoma patients undergoing 18F-FDG-PET/CT: a comparison with serologic markers of tumor burden and inflammation. Cancer Imaging, 2020, 20, 44.	2.8	13
39	Value of CT iterative metal artifact reduction in PET/CTâ€"clinical evaluation in 100 patients. British Journal of Radiology, 2019, 92, 20180756.	2.2	12
40	Effects of simulated dose variation on contrast-enhanced CT-based radiomic analysis for Non-Small Cell Lung Cancer. European Journal of Radiology, 2020, 124, 108804.	2.6	11
41	Imaging of gastrointestinal melanoma metastases: Correlation with surgery and histopathology of resected specimen. European Radiology, 2017, 27, 2538-2545.	4.5	10
42	SUV-quantification of physiological lung tissue in an integrated PET/MR-system: Impact of lung density and bone tissue. PLoS ONE, 2017, 12, e0177856.	2.5	10
43	Impact of diverse chemotherapeutic agents and external factors on activation of brown adipose tissue in a large patient collective. Scientific Reports, 2019, 9, 1901.	3.3	7
44	Determinants of activity of brown adipose tissue in lymphoma patients. Scientific Reports, 2020, 10, 21802.	3.3	5
45	Influence of 18F-FDG PET/CT on clinical management and outcome in patients with advanced melanoma not primarily selected for surgery based on a linked evidence approach. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2313-2321.	6.4	5
46	Impact of ¹⁸F-FDG-PET/CT on Clinical Management in Patients with Cholangiocellular Carcinoma. BJR|Open, 2021, 3, 20210008.	0.6	5
47	Bild gebende Diagnostik von Metastasen in Hirn, Knochen, Leber und Lunge. Onkologe, 2004, 10, 504-516.	0.7	4
48	Impact of PET/CT on management of patients with esophageal cancer â€“ results from a PET/CT registry study. European Journal of Radiology, 2021, 136, 109524.	2.6	3
49	Comparison of patient stratification by computed tomography radiomics and hypoxia positron emission tomography in head-and-neck cancer radiotherapy. Physics and Imaging in Radiation Oncology, 2020, 15, 52-59.	2.9	2
50	CT texture analysis compared to Positron Emission Tomography (PET) and mutational status in resected melanoma metastases. European Journal of Radiology, 2020, 131, 109242.	2.6	1